Nektar Therapeutics awards director rights to 6,000 shares

The RSUs and options have separate vesting terms, and the options carry a $57.66 exercise price.

Rhea-AI Filing Summary

NEKTAR THERAPEUTICS director Roy A. Whitfield received a 2,000-share restricted stock unit award and a stock option grant covering 4,000 shares on September 23, 2026. The RSUs vest in full one year following that date; the options vest in substantially equal monthly installments over the one-year period beginning that date, have a $57.66 exercise price and expire September 22, 2034. His reported direct common-stock holdings after the transactions were 16,417 shares. Reported indirect holdings were 3,434 shares by the Whitfield Family 2020 Trust and 1,334 shares by Family Trust. No Rule 10b5-1 plan is reported for the transactions.

Insider Trade Summary

Grant/Award: 6,000 shares

Grant/Award 4 txns

Insider WHITFIELD ROY A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option F4	4,000	$0.00	$0.00
Grant/Award	Common Stock F1, F2, F3	2,000	$0.00	$0.00
holding	Common Stock F3	--	--	--
holding	Common Stock F3	--	--	--

Holdings After Transaction: Stock Option — 4,000 contracts (Direct); Common Stock — 16,417 shares (Direct); Common Stock — 3,434 shares (Indirect, by Whitfield Family 2020 Trust); Common Stock — 1,334 shares (Indirect, by Family Trust)

Footnotes (4)

1. F1. Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
2. F2. This RSU award vests in full, one year following September 23, 2026.
3. F3. On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
4. F4. This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.

Key Figures

RSU award: 2,000 shares Stock option grant: 4,000 options Exercise price: $57.66 per share +4 more

7 metrics

RSU award 2,000 shares Each RSU represents a contingent right to receive one common share upon vesting.

Stock option grant 4,000 options Awarded September 23, 2026.

Exercise price $57.66 per share Stock option grant.

Option expiration September 22, 2034 Stock option grant.

Direct common-stock holdings 16,417 shares Reported following the transactions on September 23, 2026.

Whitfield Family 2020 Trust holdings 3,434 shares Reported indirect holdings on September 23, 2026.

Family Trust holdings 1,334 shares Reported indirect holdings on September 23, 2026.

Key Terms

restricted stock units, contingent right, vesting, Reverse Stock Split

4 terms

restricted stock units financial

"the common stock acquisition pursuant to a grant of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right technical

"Each RSU awarded represents a contingent right to receive"

vesting financial

"upon vesting of the unit"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Reverse Stock Split financial

"the Issuer effected a one-for-fifteen reverse stock split"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did NKTR director Roy A. Whitfield receive in awards?

Roy A. Whitfield received an award tied to 2,000 common shares through restricted stock units and a stock option grant covering 4,000 common shares on September 23, 2026. Each RSU represents a contingent right to receive one common share upon vesting.

What are the vesting terms for Roy A. Whitfield's NKTR awards?

The RSUs vest in full one year following September 23, 2026. The options vest in substantially equal monthly installments over the one-year period beginning September 23, 2026.

Was Roy A. Whitfield's NKTR award reported under a Rule 10b5-1 plan?

No Rule 10b5-1 plan is reported for the transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/25/2026 - 08:30 PM Accepted by SEC EDGAR 09/25/2026 - 08:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WHITFIELD ROY A

(Last) (First) (Middle)

C/O NEKTAR THERAPEUTICS

455 MISSION BAY BLVD SOUTH

(Street)

SAN FRANCISCO CALIFORNIA 94158

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEKTAR THERAPEUTICS [ NKTR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	09/23/2026	(2)	A		2,000	A	$0.00	16,417(3)	D
Common Stock								3,434(3)	I	by Whitfield Family 2020 Trust
Common Stock								1,334(3)	I	by Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$57.66	09/23/2026		A		4,000		(4)	09/22/2034	Common Stock	4,000	$0.00	4,000	D

Explanation of Responses:

1. Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

2. This RSU award vests in full, one year following September 23, 2026.

3. On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.

4. This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.

	Elizabeth Zhang, Attorney-in-Fact	09/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)